Other languages ISR Immune System Regulation Holding AB (publ)

Equities

Immune System Regulation AB Announces Sars-Cov-2 Dry Powder Nasal - Vaccine Booster Candidate, Isr52, Demonstrates Superior Immune Response, in Mouse Model Challenge Studies Compared to Subcutaneous injection of this vaccine	23-08-28
ISR Immune System Regulation Holding AB Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-28
ISR Immune System Regulation Holding AB Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-31
ISR Receives Approval To Conduct Clinical Trial In Bangladesh	22-07-01
ISR’s Immune System Regulation Holding AB Announces Sars-Cov-2 Vaccine Study Approved by Bangladesh Bmrc	22-07-01
ISR Immune System Regulation Holding AB Signs Development Agreements with Catalent to Scale-Up Its Spray-Dried Nasal Vaccine, Powder Formulation for Phase III	22-06-28
ISR Immune System Regulation Holding AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2021	22-02-23
ISR Immune System Regulation Holding AB Reports Earnings Results for the Full Year Ended December 31, 2021	22-02-23
Iconovo : ISR to Test Inhalable, Nasal COVID-19 Vaccines in Bangladesh	21-08-27
Isr Immune System Regulation Holding AB Publ Reports Earnings Results for the Half Year Ended June 30, 2021	21-08-25
Isr Immune System Regulation Holding AB Publ Reports Earnings Results for the Full Year Ended December 31, 2020	21-02-24

No results for this search